Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026 S4.2: prohibited at all times. Specified. [1]
S4.2 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Medical context
The EMA describes bazedoxifene, a selective estrogen-receptor modulator, in Conbriza for postmenopausal osteoporosis in women at increased fracture risk. Vertebral-fracture benefit was demonstrated; hip-fracture benefit was not established. Prior venous thromboembolism is a contraindication. [2]
- EU product context; not a worldwide availability claim.
Combination products
US Duavee combines bazedoxifene with conjugated estrogens for selected menopausal symptoms and osteoporosis prevention in women with a uterus. Its combination-product boxed warnings must not simply be assigned to bazedoxifene used alone. [3]
- A combination medicine is distinct from the single active ingredient.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · Relevant official full-text sections opened
Printed pp. 3, 9–12: introduction, S3, S4 and S5 as applicable
- EMA Conbriza ↗Accessed 2026-11-10 · Relevant document text opened
Relevant cited sections
- Duavee conjugated estrogens/bazedoxifene ↗Accessed 2026-11-10 · Current label highlights and selected full-text sections
Indications and Usage; formulation; Warnings and Precautions; selected interactions/clinical pharmacology
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.